Aegerion Pharmaceuticals (AEGR) Clinical Update on Its Lomitapide (visto 3 veces)

Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. Aegerion Pharmaceuticals Incorporated - AEGR - provided a clinical update on its lomitapide. Aegerion reported that the 78-week data from its pivotal Phase III clinical trial is consistent with data previously reported at the 26- and 56-week time points. According to the company, the data demonstrate that the reduction in LDL-C cholesterol from baseline was maintained at 78-weeks. Aegerion Pharmaceuticals’ Lomitapide is being evaluated for its ability to reduce low density lipoprotein (LDL-C) or bad cholesterol levels in patients with homozygous familial hypercholesterolemia. Aegerion Pharmaceuticals aspires to change the way rare, genetic lipid disorders are treated. Thanks for joining me and have a great day! For CRWE Newswire, Stocks to watch, I’m Shalika Jayasekera *********** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

Categoría: Ciencia y tecnología

Añadido: 8 Jan de 2012

Tags: Aegerion AEGR Nasdaq:AEGR lomitapide LDL-C

(Menos información)